Premier cas de syndrome d’activation macrophagique secondaire à une hépatite virale E (VHE) chez un patient atteint d’un lymphome splénique
Mathilde Le Brun(Servier (France)), Gilles Kaplanski(Hôpital Sainte-Marguerite), Jean‐Robert Harlé(Hôpital de la Timone), K. Mazodier(Hôpital de la Conception), Laure Farnault(Aix-Marseille Université), Rene Costello(National Institutes of Health), Bruno Chetaille(Institut Paoli-Calmettes)
Cited by 1
Related Papers
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey
|Blood Cancer Journal|2017|116
Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors
|Blood Cancer Journal|2016|74